PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26864332-12	2016	In vitro, suvorexant demonstrated reversible inhibition of CYP3A4 and 2C19 (IC50 ~ 4-5 muM), and weak time-dependent inhibition of CYP3A4 (KI = 12 muM, kinact = 0.14 min(-1)).	suvorexant	10-20	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	59-74	
26864332-12	2016	In vitro, suvorexant demonstrated reversible inhibition of CYP3A4 and 2C19 (IC50 ~ 4-5 muM), and weak time-dependent inhibition of CYP3A4 (KI = 12 muM, kinact = 0.14 min(-1)).	suvorexant	10-20	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	59-65	
26864332-13	2016	Suvorexant was also a weak inducer of CYP3A4, 1A2 and 2B6.	suvorexant	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	38-44	
27191770-8	2016	DISCUSSION: Because suvorexant is metabolized by CYP3A4, next-day somnolence could have occurred as a result of increased plasma suvorexant concentration due to CYP3A4 inhibition by diltiazem.	suvorexant	20-30	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	49-55	
27191770-8	2016	DISCUSSION: Because suvorexant is metabolized by CYP3A4, next-day somnolence could have occurred as a result of increased plasma suvorexant concentration due to CYP3A4 inhibition by diltiazem.	suvorexant	20-30	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	161-167	
27191770-8	2016	DISCUSSION: Because suvorexant is metabolized by CYP3A4, next-day somnolence could have occurred as a result of increased plasma suvorexant concentration due to CYP3A4 inhibition by diltiazem.	suvorexant	129-139	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	161-167	
30810914-2	2019	As suvorexant is metabolized primarily by Cytochrome P450 3A (CYP3A), and its pharmacokinetics may be affected by CYP3A modulators, the effects of CYP3A inhibitors (ketoconazole or diltiazem) or an inducer (rifampin [rifampicin]) on the pharmacokinetics, safety, and tolerability of suvorexant were investigated.	suvorexant	3-13	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	42-60	
30810914-2	2019	As suvorexant is metabolized primarily by Cytochrome P450 3A (CYP3A), and its pharmacokinetics may be affected by CYP3A modulators, the effects of CYP3A inhibitors (ketoconazole or diltiazem) or an inducer (rifampin [rifampicin]) on the pharmacokinetics, safety, and tolerability of suvorexant were investigated.	suvorexant	3-13	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	62-67	
30810914-2	2019	As suvorexant is metabolized primarily by Cytochrome P450 3A (CYP3A), and its pharmacokinetics may be affected by CYP3A modulators, the effects of CYP3A inhibitors (ketoconazole or diltiazem) or an inducer (rifampin [rifampicin]) on the pharmacokinetics, safety, and tolerability of suvorexant were investigated.	suvorexant	3-13	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	114-119	
30810914-2	2019	As suvorexant is metabolized primarily by Cytochrome P450 3A (CYP3A), and its pharmacokinetics may be affected by CYP3A modulators, the effects of CYP3A inhibitors (ketoconazole or diltiazem) or an inducer (rifampin [rifampicin]) on the pharmacokinetics, safety, and tolerability of suvorexant were investigated.	suvorexant	3-13	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	114-119	
30895461-0	2019	Correction to: Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects.	suvorexant	83-93	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	25-30	
26648692-5	2015	Suvorexant is metabolized by the hepatic CYP3A system and should be avoided in combination with strong CYP3A inhibitors.	suvorexant	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	41-46	
26648692-5	2015	Suvorexant is metabolized by the hepatic CYP3A system and should be avoided in combination with strong CYP3A inhibitors.	suvorexant	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	103-108